pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution Nov 7, 2017 06:00AM
pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information Oct 18, 2017 07:00AM
pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma Oct 10, 2017 07:00AM
pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs Sep 26, 2017 07:00AM
pSivida to Present at the Ladenburg Thalmann 2017 Healthcare Conference Sep 22, 2017 02:29PM
View Older Stories

Sep 11, 2017 04:01PM pSivida Corp. Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results
Sep 11, 2017 07:00AM pSivida to Present at Rodman & Renshaw Annual Global Investment Conference
Sep 5, 2017 07:00AM pSivida Corp. to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Monday, September 11th
Aug 1, 2017 07:00AM pSivida to Present at Canaccord Genuity Growth Conference on August 10, 2017
Jul 18, 2017 07:00AM Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences
Jul 10, 2017 04:10PM pSivida (PSDV) Out-licenses EMEA Rights for Durasert While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera (ALIM) for ILUVIEN Improves pSivida's Revenue Generatio
Jul 10, 2017 04:01PM pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUV
Jun 28, 2017 07:00AM pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson
Jun 22, 2017 07:02AM pSivida (PSDV) Submits MAA for Approval of Durasert Three-year Treatment for Posterior Segment Uveitis in EU
Jun 22, 2017 07:00AM pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert™ Three-year Treatment for Posterior Segment Uveitis in the European Union
Jun 13, 2017 07:03AM pSivida's (PSDV) Three-year Treatment for Posterior Segment Uveitis Achieves Primary Efficacy Endpoint in Second Phase 3 Study
Jun 13, 2017 07:00AM pSivida’s Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
May 8, 2017 09:17AM pSivida (PSDV) Announces Positive Durasert 3-Year Treatment Data
May 8, 2017 09:15AM Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months
May 4, 2017 04:01PM pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track
Apr 19, 2017 04:01PM pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th
Mar 15, 2017 07:11AM pSivida (PSDV) Says Abstract on Treatment of Posterior Segment Uveitis Accepted for Presentation at ARVO
Mar 15, 2017 07:00AM Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Feb 10, 2017 07:00AM pSivida to Present at the 2017 BIO CEO & Investor Conference
Feb 7, 2017 04:01PM pSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results
Jan 25, 2017 07:00AM pSivida Corp. Announces Second Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information
Nov 7, 2016 04:15PM Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development
Nov 7, 2016 04:01PM pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline
Oct 31, 2016 07:00AM pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information
Oct 4, 2016 07:04AM pSivida (PSDV) Completes Enrollment of Second Medidur Phase 3
Oct 4, 2016 07:00AM Phase 3 trial of Medidur™ in Posterior Segment Uveitis Meets Enrollment Target
Sep 27, 2016 07:08AM pSivida (PSDV) Appoints New Director
Sep 27, 2016 07:00AM pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist
Sep 22, 2016 09:00AM pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference
Sep 20, 2016 04:01PM pSivida Reports Inducement Awards to New President and Chief Executive Officer
Sep 15, 2016 07:07AM pSivida (PSDV) Makes Leadership Changes, Including New CEO Appointment
Sep 15, 2016 07:00AM pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO
Sep 12, 2016 04:01PM pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results
Sep 1, 2016 10:00AM pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Aug 29, 2016 10:01AM pSivida (PSDV) Announces Receipt of 13 New Domestic, Foreign Patents, Allowed Applications
Aug 29, 2016 10:00AM pSivida Announces 13 New Patents Issued or Allowed
Aug 15, 2016 09:06AM pSivida (PSDV) Says Results from First Phase 3 Trial of Medidur Presented at ASRS
Aug 15, 2016 09:00AM Topline Results from First Phase 3 Trial of pSivida’s Medidur™ Presented at ASRS Annual Meeting
Aug 9, 2016 10:01AM pSivida (PSDV) Says Medidur Inserter Utilization Study with Smaller-Diameter Needle Met Primary Endpoint
Aug 9, 2016 10:00AM Primary Endpoint Met in pSivida’s Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle
Aug 3, 2016 08:14AM pSivida (PSDV) Appoints New Chief Medical Officer
Aug 3, 2016 08:00AM pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer
Aug 1, 2016 07:00AM pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis
Jul 27, 2016 07:35AM pSivida (PSDV) Reports First Medidur Phase 3 as PU Treatment Met Primary Endpoint
Jul 27, 2016 07:30AM pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)
Jul 20, 2016 08:04AM pSivida (PSDV) Announces Presentation of New Tethadur bioerodible Tech Data; Retained High Activity Noted
Jul 20, 2016 08:00AM Data Shows pSivida’s Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy
Jul 15, 2016 08:03AM pSivida (PSDV) Plans to Consolidate Malvern R&D Facility
Jul 15, 2016 08:00AM pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility
Jul 14, 2016 11:10AM pSivida (PSDV) Says Investigator-Sponsored Phase 2 Study Results Show Medidur Fully Controlled Uveitis
View Older Stories